SEC comment letter
SEC correspondence
SEC staff questioned Telix Pharmaceuticals Ltd's accounting for non-GAAP measures
Letter dated 2026-04-03; published on EDGAR 2026-10-20 — the SEC releases comment letters only after the review closes.
We note that you present Adjusted EBITDAR, a non-IFRS measure, that adjusts for costs associated with research and development costs and revenue from contracts with customers. Please tell us how you considered the guidance in Item 10(e) of Regulation S-K and Question 100.01 of the Non-GAAP Corporation Finance Interpretations in presenting this non-IFRS measure and explain why these adjustments are appropriate. In…
Evidence
- Direction
- staff to company
- Letter dated
- 2026-04-03
- Published on edgar
- 2026-10-20
- Reviewing
- Telix Pharmaceuticals Limited Form 20-F for Fiscal Year Ended December 31, 2025 File No. 001-42128 Dear Darren Smith: We have limited our review of your filing
- Source
- SEC staff comment letter (UPLOAD)
- Topics
- Non-GAAP measures
- Why
- SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.